Peter Clark to Animals
This is a "connection" page, showing publications Peter Clark has written about Animals.
Connection Strength
0.448
-
Polosukhina D, Love HD, Moses HL, Lee E, Zent R, Clark PE. Pharmacologic Inhibition of ß-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor. Oncol Res. 2017 Nov 02; 25(9):1653-1664.
Score: 0.064
-
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol. 2017 04; 11(4):405-421.
Score: 0.063
-
Yi Y, Polosukhina D, Love HD, Hembd A, Pickup M, Moses HL, Lovvorn HN, Zent R, Clark PE. A Murine Model of K-RAS and ß-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor. J Urol. 2015 Dec; 194(6):1762-70.
Score: 0.055
-
Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman EJ, de Caestecker M, Moses HL, Zent R. ß-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors. Am J Pathol. 2011 Dec; 179(6):3045-55.
Score: 0.043
-
Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 2009 Nov; 76(9):939-45.
Score: 0.037
-
Clark PE. Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol. 2007 Sep; 17(5):331-6.
Score: 0.032
-
Kumar B, Ahmad R, Giannico GA, Zent R, Talmon GA, Harris RC, Clark PE, Lokeshwar V, Dhawan P, Singh AB. Claudin-2 inhibits renal clear cell carcinoma progression by inhibiting YAP-activation. J Exp Clin Cancer Res. 2021 Feb 23; 40(1):77.
Score: 0.021
-
Nlandu-Khodo S, Neelisetty S, Phillips M, Manolopoulou M, Bhave G, May L, Clark PE, Yang H, Fogo AB, Harris RC, Taketo MM, Lee E, Gewin LS. Blocking TGF-ß and ß-Catenin Epithelial Crosstalk Exacerbates CKD. J Am Soc Nephrol. 2017 Dec; 28(12):3490-3503.
Score: 0.016
-
Austin DC, Strand DW, Love HL, Franco OE, Grabowska MM, Miller NL, Hameed O, Clark PE, Matusik RJ, Jin RJ, Hayward SW. NF-?B and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate. 2016 08; 76(11):1004-18.
Score: 0.015
-
Richmond BW, Brucker RM, Han W, Du RH, Zhang Y, Cheng DS, Gleaves L, Abdolrasulnia R, Polosukhina D, Clark PE, Bordenstein SR, Blackwell TS, Polosukhin VV. Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency. Nat Commun. 2016 Apr 05; 7:11240.
Score: 0.015
-
Grabowska MM, Kelly SM, Reese AL, Cates JM, Case TC, Zhang J, DeGraff DJ, Strand DW, Miller NL, Clark PE, Hayward SW, Gronostajski RM, Anderson PD, Matusik RJ. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia. Endocrinology. 2016 Mar; 157(3):1094-109.
Score: 0.014
-
Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA, Smith JA, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Am J Pathol. 2015 May; 185(5):1385-95.
Score: 0.014
-
Lin-Tsai O, Taylor JA, Clark PE, Adam RM, Wu XR, DeGraff DJ. Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):512-6.
Score: 0.013
-
Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Matusik RJ. NF-?B gene signature predicts prostate cancer progression. Cancer Res. 2014 May 15; 74(10):2763-72.
Score: 0.013
-
Clayton DB, Stephany HA, Ching CB, Rahman SA, Tanaka ST, Thomas JC, Pope JC, Adams MC, Brock JW, Clark PE, Hayward SW, Matusik RJ, Milne GL. F2-isoprostanes as a biomarker of oxidative stress in the mouse bladder. J Urol. 2014 May; 191(5 Suppl):1597-601.
Score: 0.013
-
DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7(5):e36669.
Score: 0.011
-
Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW. PPAR?: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation. 2011 Nov-Dec; 82(4-5):220-36.
Score: 0.010